Behavioral improvement in a primate Parkinson’s model is associated with multiple homeostatic effects of human neural stem cells.
Redmond, D.E., Bjugstad, K.B., Teng, Y.D., et al. Proc. Nat’l Acad. Sci., 104, 12175-12180 (July 17, 2007)
Discovered decades ago, L-DOPA and other drugs that raise dopamine levels remain key elements in our pharmacopeia for Parkinson’s disease. More recently, attempts have been made to replace the lost neurons of the substantia nigra with fetal dopamine neurons, unfortunately with limited success. Results of the current paper suggest that pluripotent neural stem cells may constitute an alternative.
Using a primate model for Parkinson’s (treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or MPTP), the authors demonstrated that implantation of human neural stem cells into the substantia nigra and bilaterally into the caudate nucleus (1 million per site) significantly reduced the behavioral traits associated with the disease over a four-month period. A histological examination revealed that stem cells injected near the right substantia nigra migrated through the nigrostriatal pathway.
Histological examinations of the human neural stem cells at seven to eight months post-implantation found that some had begun production of two key components of the dopaminergic signaling system, tyrosine hydroxylase and the dopamine transporter protein. Other donor cells were found associated with tyrosine hydroxylase-positive host cells that had increased in size during seven months after the stem cell therapy was performed. These donor cells expressed markers characteristic of an astrocytic cell lineage, glial fibrillary protein and glia-derived neurotrophic factor.
The results suggest that the human neural stem cells differentiated after implantation, some forming dopaminergic neurons that may have directly mitigated the effects of the experimentally induced Parkinson’s disease and others forming glia that may have helped to sustain the still-viable cells of the host’s substantia nigra. Long-term primate studies are now needed to decide whether this stem cell therapy merits consideration for clinical application.
Message posted by: Keith Markey
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...